AI assistant
Ocugen, Inc. — Director's Dealing 2015
Jul 31, 2015
32915_dirs_2015-07-31_bbf6d742-e24e-44fd-918d-99b4e83983a9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2015-07-29
Reporting Person: Matthews Gloria (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-07-29 | Employee Stock Option (Right to Buy) | $6.11 | A | 120000 | Acquired | 2025-07-29 | Common Stock (120000) | Direct |
| 2015-07-29 | Employee Stock Option (Right to Buy) | $6.11 | A | 30000 | Acquired | 2025-07-29 | Common Stock (30000) | Direct |
Footnotes
F1: This option vests over four (4) years of continuous service following July 14, 2015, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and the balance vesting in thirty-six (36) equal monthly installments thereafter.
F2: This option shall vest in full if the Issuer's Common Stock price reaches $19.92 per shares or above for any consecutive sixty (60) day period within four (4) years of the date of grant (the date such option vests, the "Vesting Date"). In addition, if this option is exercised within one (1) year of the Vesting Date, the Reporting Person must hold shares (net of taxes) until the one (1) year anniversary of the Vesting Date.